Development of novel measures for Alzheimer's disease prevention trials (NoMAD).

ABSTRACT:

Introduction

Assessment of cognition and everyday function is essential in clinical trials for Alzheimer's disease (AD). Two novel measures of cognition (No Practice Effects (NPE) cognitive battery and Miami Computerized Functional Assessment Scale (CFAS)) were designed to have robust psychometric properties and reduced practice and ceiling effects. This study aims to evaluate if the NPE and CFAS demonstrate stronger psychometric properties and reduced practice effects compared with established measures, including the Preclinical Alzheimer Cognitive Composite (PACC), Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), and Functional Activities Questionnaire (FAQ).

Methods

This parallel group, four-site study will randomize 320 cognitively intact adults aged 6

SUBMITTER: Bell SA 

PROVIDER: S-EPMC10001317 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature